Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists.
Cannabis
chronic kidney disease
chronic pain
end-stage kidney disease
nephrologists
survey
symptoms management
Journal
Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
Cannabis use may be helpful for symptom management in patients with chronic kidney disease (CKD). Knowledge, attitudes, and comfort with use of medical cannabis among kidney care providers may be limiting more widespread evaluation and use. We surveyed Canadian nephrologists regarding current prescribing habits, attitudes, and overall comfort level with cannabis products. We carried out a nationwide, mail-in survey focused on capturing general and practice demographics, current cannabis prescribing status, and knowledge and attitudes regarding therapeutic cannabis use in patients with CKD. This survey was distributed to every registered nephrologist in Canada. The results of this survey are reported descriptively. Responses were received from 208 of 723 (29%) nephrologists. Only 21 (10.1%) respondents currently prescribe cannabis, with chronic pain syndromes being the most frequent reason for cannabis prescription (95.2%). Overall, 116 (55.5%) participants reported that changes in legality of cannabis did not influence their decision to prescribe cannabis. The majority of respondents (n = 123; 59%) indicated that they were uncomfortable with their knowledge of the medical cannabis literature. Most respondents (n=188; 91%) indicated that further studies exploring the efficacy and safety of cannabis would likely influence their prescribing habits. Limitations of this study include possible nonresponse bias and a lack of specific data on practice considerations for specific subpopulations, such as transplant patients. Only a small minority of Canadian nephrologists currently prescribe cannabis, with relatively little practice change after legalization. There is broad support amongst Canadian nephrologists for encouraging their patients to enroll in efficacy/safety studies of cannabis in the CKD population. Ultimately, given limited therapeutic options available for symptom control in CKD, this survey demonstrates the potential for nationwide practice change if cannabis efficacy and safety can be demonstrated in this population.
Identifiants
pubmed: 35518836
doi: 10.1016/j.xkme.2022.100453
pii: S2590-0595(22)00066-8
pmc: PMC9065896
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100453Informations de copyright
© 2022 The Authors.
Références
Cannabis Cannabinoid Res. 2020 Jun 05;5(2):172-182
pubmed: 32656349
J Am Soc Nephrol. 2017 Dec;28(12):3658-3670
pubmed: 28935654
J Pain Symptom Manage. 2021 Feb;61(2):237-245.e2
pubmed: 32805405
J Pain Symptom Manage. 2011 Apr;41(4):768-78
pubmed: 21269798
Am J Transplant. 2019 Oct;19(10):2944-2948
pubmed: 31012522
Drug Alcohol Depend. 2017 Apr 01;173:144-150
pubmed: 28259087
Health Aff (Millwood). 2016 Jul 1;35(7):1230-6
pubmed: 27385238
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Cannabis Cannabinoid Res. 2018 Mar 01;3(1):45-53
pubmed: 29607410
Cannabis Cannabinoid Res. 2018 Oct 01;3(1):195-202
pubmed: 30426072
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):435-42
pubmed: 25710806
J Clin Pharmacol. 2002 Nov;42(S1):58S-63S
pubmed: 12412837
Clin J Am Soc Nephrol. 2018 Jul 6;13(7):993-1001
pubmed: 29880471
Cannabis Cannabinoid Res. 2018 Mar 01;3(1):74-84
pubmed: 29662957
Am J Kidney Dis. 2018 Feb;71(2):267-274
pubmed: 28811049
Cochrane Database Syst Rev. 2015 Nov 12;(11):CD009464
pubmed: 26561338
Front Public Health. 2018 Aug 06;6:220
pubmed: 30128310
J Renal Inj Prev. 2016 Sep 03;6(1):49-55
pubmed: 28487872
Acta Dermatovenerol Croat. 2005;13(2):97-103
pubmed: 16324422
J Pain. 2015 Dec;16(12):1221-1232
pubmed: 26362106
Case Rep Transplant. 2016;2016:4028492
pubmed: 27595035
JAMA Intern Med. 2014 Oct;174(10):1668-73
pubmed: 25154332
Psychopharmacology (Berl). 2005 Aug;181(1):170-8
pubmed: 15778874
Am J Emerg Med. 2020 Sep;38(9):1952-1954
pubmed: 32067838
Psychosomatics. 2019 Nov - Dec;60(6):603-605
pubmed: 30819507
Can J Kidney Health Dis. 2019 Feb 22;6:2054358119828391
pubmed: 30828459
Ann Intern Med. 2017 Sep 05;167(5):319-331
pubmed: 28806817
Am J Hosp Palliat Care. 2017 Feb;34(1):85-91
pubmed: 26377551
J Pain Symptom Manage. 2010 Feb;39(2):167-79
pubmed: 19896326